HK1247789A1 - 用於治疗水肿的组合物和方法 - Google Patents

用於治疗水肿的组合物和方法 Download PDF

Info

Publication number
HK1247789A1
HK1247789A1 HK18107279.7A HK18107279A HK1247789A1 HK 1247789 A1 HK1247789 A1 HK 1247789A1 HK 18107279 A HK18107279 A HK 18107279A HK 1247789 A1 HK1247789 A1 HK 1247789A1
Authority
HK
Hong Kong
Prior art keywords
methods
edema
compositions
treatment
agent
Prior art date
Application number
HK18107279.7A
Other languages
English (en)
Chinese (zh)
Inventor
Mehrara Babak
Gardenier Jason
SAVETSKY Ira
ARAS Omer
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of HK1247789A1 publication Critical patent/HK1247789A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
HK18107279.7A 2015-02-05 2016-02-05 用於治疗水肿的组合物和方法 HK1247789A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562112273P 2015-02-05 2015-02-05
US62/112,273 2015-02-05
PCT/US2016/016680 WO2016127013A1 (en) 2015-02-05 2016-02-05 Compositions and methods for treatment of edema

Publications (1)

Publication Number Publication Date
HK1247789A1 true HK1247789A1 (zh) 2018-10-05

Family

ID=56564721

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18107279.7A HK1247789A1 (zh) 2015-02-05 2016-02-05 用於治疗水肿的组合物和方法

Country Status (9)

Country Link
US (5) US10251871B2 (enExample)
EP (1) EP3253211B1 (enExample)
JP (2) JP6704403B2 (enExample)
CN (2) CN114588154A (enExample)
AU (2) AU2016215173B2 (enExample)
CA (1) CA2975879A1 (enExample)
ES (1) ES3040783T3 (enExample)
HK (1) HK1247789A1 (enExample)
WO (1) WO2016127013A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1247789A1 (zh) * 2015-02-05 2018-10-05 Memorial Sloan Kettering Cancer Center 用於治疗水肿的组合物和方法
EP3500308A4 (en) * 2016-08-18 2020-04-22 Memorial Sloan Kettering Cancer Center INHIBITION OF THE SPHINGOSIN-1-PHOSPHATE RECEPTOR FOR TREATING AND PREVENTING LYMPHEDEMES
MX2021002916A (es) * 2018-09-14 2021-08-24 Puretech Lyt 100 Inc Pirfenidona enriquecida con deuterio y métodos para su uso.
EP3876905A4 (en) * 2018-11-05 2022-08-03 Apramitha Innovations Private Limited Teriflunomide topical pharmaceutical compositions
WO2021186401A1 (en) * 2020-03-18 2021-09-23 Puretech Lyt 100, Inc. Methods of treating lymphedema with deupirfenidone
CN112642065B (zh) * 2020-12-28 2022-08-02 锐可医疗科技(上海)有限公司 激光治疗仪及存储介质
WO2024059336A1 (en) * 2022-09-18 2024-03-21 Memorial Sloan Kettering Cancer Center Inhibition of protease-activated receptor 2 (par2) pathway for treatment and prevention of lymphedema

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005011669A1 (ja) * 2003-08-05 2005-02-10 Dainippon Sumitomo Pharma Co., Ltd. 経皮投与用医薬組成物
US20050158371A1 (en) * 2002-02-12 2005-07-21 Sumitomo Pharmaceuticals Co., Ltd. Novel external agent
US7232828B2 (en) * 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
WO2007103687A2 (en) * 2006-03-01 2007-09-13 Tristrata, Inc. Composition and method for topical treatment of tar-responsive dermatological disorders
CN101443004B (zh) * 2006-03-23 2013-03-06 参天制药株式会社 用于与血管通透性有关的疾病或病症的制剂
EP2036555B1 (en) * 2006-06-15 2011-11-16 Shanghai Genomics, Inc. The use of pyridone derivatives for preventing and treating radiation injury of lungs
CA2823407C (en) * 2007-03-22 2016-10-18 Berg Pharma Llc Topical formulations having enhanced bioavailability
WO2010048716A1 (en) * 2008-10-29 2010-05-06 Pacific Therapeutics Ltd. Composition and method for treating fibrosis
US7635707B1 (en) * 2008-11-10 2009-12-22 Intermune, Inc. Pirfenidone treatment for patients with atypical liver function
WO2010091140A1 (en) * 2009-02-04 2010-08-12 Bipar Sciences, Inc. Treatment of lung cancer with a parp inhibitor in combination with a growth factor inhibitor
DE102010015143A1 (de) * 2010-04-16 2011-10-20 Cts Chemical Industries Ltd. Stabile flüssige ölige gebrauchsfertige Formulierungen, Herstellung davon und Verwendung davon
HK1247789A1 (zh) * 2015-02-05 2018-10-05 Memorial Sloan Kettering Cancer Center 用於治疗水肿的组合物和方法
US10292961B2 (en) * 2015-07-15 2019-05-21 Hangzhou Dac Biotech Co., Ltd. Disulfur bridge linkers for conjugation of a cell-binding molecule

Also Published As

Publication number Publication date
CN107427007A (zh) 2017-12-01
US20230241043A1 (en) 2023-08-03
ES3040783T3 (en) 2025-11-04
JP6926263B2 (ja) 2021-08-25
AU2020201161B2 (en) 2021-07-15
JP2020114830A (ja) 2020-07-30
CN114588154A (zh) 2022-06-07
WO2016127013A1 (en) 2016-08-11
US10251871B2 (en) 2019-04-09
US20250235436A1 (en) 2025-07-24
EP3253211A1 (en) 2017-12-13
CN107427007B (zh) 2022-02-11
CA2975879A1 (en) 2016-08-11
EP3253211A4 (en) 2018-10-31
AU2020201161A1 (en) 2020-03-05
US12144805B2 (en) 2024-11-19
EP3253211B1 (en) 2025-06-11
JP2018504436A (ja) 2018-02-15
JP6704403B2 (ja) 2020-06-03
US20210069164A1 (en) 2021-03-11
AU2016215173A1 (en) 2017-08-24
US20180028514A1 (en) 2018-02-01
US20200016137A1 (en) 2020-01-16
AU2016215173B2 (en) 2019-11-21
US11583523B2 (en) 2023-02-21
US10874651B2 (en) 2020-12-29

Similar Documents

Publication Publication Date Title
HK1247789A1 (zh) 用於治疗水肿的组合物和方法
NZ742208A (en) Topical pharmaceutical formulations for treating inflammatory-related conditions
MX2018002723A (es) Macrociclicos peptidomimeticos y usos de los mismos.
MX2018012486A (es) Composiciones para aplicacion topica de compuestos.
TW201613887A (en) Antiproliferative compounds and methods of use thereof
MX2018006223A (es) Moduladores de ror-gamma.
MY199705A (en) Heterocyclic compounds as immunomodulators
NZ737004A (en) Triazole agonists of the apj receptor
MY198613A (en) Nitrobenzyl derivatives of anti-cancer agents
WO2015070224A3 (en) Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
WO2016004305A3 (en) Inhibitors of bruton's tyrosine kinase
MX371304B (es) Dihidropirrolopiridinas inhibidoras del receptor huérfano-gamma.
MX2016010034A (es) Inhibidores de dihidropirrolopiridina de receptor huerfano relacionado-gamma.
HK1216083A1 (zh) 经动脉的药物递送
WO2018019823A8 (en) Administration and dosage of diaminophenothiazines
WO2016089206A3 (en) Selective il-6-trans-signalling inhibitor compositions
WO2017142895A8 (en) Compositions and methods for treating clostridium associated diseases
WO2015126930A3 (en) Booster drug therapy for mycobacterium infections
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
MX2017010422A (es) Imidazolil enonas triciclicas como moduladores de inflamacion antioxidantes.
WO2016130581A3 (en) Combination cancer therapy
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
MX381311B (es) Método para el tratamiento de prurito y/o comezón.
MY178960A (en) Hiv treatment formulation of atazanavir and cobicistat
WO2017079403A3 (en) Polymeric nanoparticles